EU approves Roche drug Columvi for lymphoma treatment

Roche: EU approves Columvi for lymphoma treatment Keystone-SDA

The European Commission has approved Roche's Columvi as the first bispecific antibody for the treatment of diffuse large B-cell lymphoma after initial therapy, the pharmaceutical giant announced on Monday.

+Get the most important news from Switzerland in your inbox

The approval is based on the result of the phase III Starglo trial, during which Columvi – combined with Gemcitabine and oxaliplatin (GemOx) – demonstrated a “statistically and clinically significant improvement in survival” compared to other treatments, Roche explained.

+ How drug prices are negotiated in Switzerland and beyond

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a high risk of progression, which means that urgent and effective treatments are needed. In primary analyses, a 41% reduction in the risk of death was found among patients treated with Columvi and GemOx.

Translated from Italian by DeepL/ts

How we work

We select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate them into English. An editor then briefly reviews the translation for clarity and accuracy before publication. Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.

Did you find this explanation helpful? Please fill out this short survey to help us understand your needs: https://survey.survicate.com/d0df481d0b13412d/?p=anonymousExternal link